New cancer-specific molecular changes that could potentially inform the development of cancer treatments have been uncovered by scientists at ETH Zurich.
A research team led by Gunnar Rätsch, Professor of Biomedical Informatics at ETH Zurich, evaluated the largest set of genetic data in cancer medicine: The Cancer Genome Atlas. The Atlas compiles genetic information on tumor cells from several thousand cancer patients and 33 types of cancer at DNA and RNA level.
Many previous genetic analyses of cancer cells have concentrated on their DNA – the “basic” version of the genetic information. Such studies examined genes to see if they contained tumor-specific mutations. In addition, it was studied if the genes were especially active or inactive depending on the tumor.
The ETH researchers have gone a step further and taken a closer look at the RNA molecules, which are responsible for transcribing the cell’s DNA.
Before RNA molecules can serve as a blueprint for the biosynthesis of proteins, they undergo a series of transformative cellular processes: in a process called splicing, specialised enzymes cut out entire sections from the RNA molecule and join the sequences on either side together.
An RNA molecule can be spliced in a range of different ways, which experts refer to as “alternative splicing”. In other words, as a copy of a gene an RNA molecule can deliver the blueprint for various protein forms, the groundwork for which is laid during splicing.
In their analysis for tumor-specific alternative splicing, Rätsch and his colleagues looked at an unprecedented volume of genetic cancer data, examining sequences in RNA molecules from 8,700 cancer patients. They found several ten thousand previously undescribed variants of alternative splicing that crop up over and over in many cancer patients.
The researchers were also able to show that in the majority of the cancer types tested, alternative splicing occurred much more frequently in tumor tissues than in healthy tissues. It is especially pronounced in pulmonary adenocarcinomas, where alternative splicing occurs 30 percent more frequently than in healthy samples.
Sand In The Gearbox
Thanks to this study, the researchers gained new insights into which molecular factors cause the high rate of alternative splicing in cancer cells. Some genetic mutations that encourage alternative splicing are already known, but now the team was able to identify another four genes involved.
“Cancer leads to molecular and functional changes in cells. You could say that in cancer cells, there’s lots of sand in the gears. At the molecular level the changes come not only in the form of individual DNA mutations, which we’ve known about for a long time, but also to a great extent in the form of different kinds of RNA splicing, as we were able to show in our comprehensive analysis,”
says André Kahles, a postdoc in Rätsch’s group and one of the study’s two lead authors.
Not all of the newly discovered molecular changes in RNA necessarily also cause functional changes in cancer cells, the researchers say. Still, the molecular differences can inform novel therapy approaches – for instance, cells that feature splicing patterns typical for cancer could be treated with immunotherapy.
Non-targeted Cancer Immunotherapy
In targeted cancer immunotherapy, the body’s own immune system is trained to recognise typical molecular cancer markers so it can attack and kill cancer tissue. Healthy body tissue is left alone.
At present only a minority of cancer patients can be treated with this method, since tumor-specific markers suitable for use in immunotherapy were present in only some 30 percent of cases. The newly discovered variations of alternative splicing lead to changes in proteins that in turn can also serve as tumor-specific markers: up to 75 percent of cases were found to exhibit these new markers that could potentially be used for developing specific medications.
Simply obtaining information on the frequency of alternative splicing is in itself highly valuable.
Specifically, the scientists theorise that tumor tissue with many splicing operations is particularly vulnerable to another type of immunotherapy, namely non-targeted immunotherapy. They wish to explore this hypothesis as part of the ETH Domain’s Personalized Health and Related Technologies (PHRT) research programme.
André Kahles, Kjong-Van Lehmann, Nora C. Toussaint, Matthias Hüser, Stefan G.Stark, Timo Sachsenberg, Oliver Stegle, Oliver Kohlbacher, Chris Sander
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients
Cancer Cell https://doi.org/10.1016/j.ccell.2018.07.001
Image: iStock.com / selvanegra / comotion_design, Montage: ETH Zurich